WALTHAM - Zenas BioPharma, Inc. ('Zenas' or the 'Company') (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company advancing therapies for patients living with autoimmun ...

A large study finds that nearly half of CAR T-cell therapy recipients develop a respiratory viral infection, and most infections occur after day 100.

For children with high-risk B-cell acute lymphoblastic leukemia (ALL), replacing part of their intensive chemotherapy with ...

Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug. Click for more ...

Full one-year results from the KYSA-8 registrational trial in stiff person syndrome to be reported, demonstrating sustained clinical benefit and ...

Veronika Bachanova, MD, PhD, discussed how the favorable safety profile of CAR natural killer cell therapies may come with ...

A two-year real-world study found that ofatumumab sustained B-cell depletion in multiple sclerosis patients while producing ...

Late-breaking oral presentation will highlight initial clinical results evaluating azer-cel, an allogeneic “off-the-shelf” CD19-directed CAR T-cell therapy, in patients with progressive multiple ...

Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader ...

CAR-T therapy, which transformed the treatment of B-cell blood cancers, is now being tested as a way to reset the immune system in severe ...

INDICATION AUCATZYL ® is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adult patients with relapsed or refractory B-cell precursor acute ...

Imugene Reports New Responses With Azercabtagene Zapreleucel Plus BTK Inhibitor in Phase 1b Blood Cancer Trial / allogeneic ...